High Purity >99% Tirzepatide a ni.

Tirzepatide hi novel, injectable damdawi a ni a, type 2 diabetes leh obesity enkawlna atana hman ber a ni. Tirzepatide hi dual agonist a ni a, thisen sugar leh appetite regulate-na atana inrawlh hormone pawimawh pahnih a target a ni-glucagon-peptide-1 (GLP{8}1) leh glucose-dependent insulinotropic peptide (GIP) ang chi te a target a ni. Heng hormone-te hnathawh ang chiah hian Tirzepatide hian insulin sensitivity a ti tha a, glucose level a ti regulate a, ei duhna a ti tlem a, chu chuan zunthlum leh taksa rihna nena inzawm thil enkawltute tan duhthlan tur beisei awm tak a siam a ni.
Damdawi hian chaw ei tur chhanna atana insulin secretion tihpun te, glucagon secretion tihhniam (chu chuan liver glucose siam chhuah tihtlem nan a pui a), leh gastric emptying tihtlem te hmangin hna a thawk a ni. Heng thiltih inzawmkhawmte hian ei zawh hnua thisen sugar level control-na atan a pui a, satiety tihhmasawn hmangin taksa rihna tihtlem a pui bawk. Tin, Tirzepatide hian HbA1c (long-term blood sugar control atana marker) nasa takin a tihhniam bakah clinical trial-ah taksa rihna a tisang tih hmuhchhuah a ni bawk a, hei hian zunthlum leh thau lutuk vanga harsatna tawk damlote tan pawh duhthlan tur ngaihnawm tak a ni tih hmuhchhuah a ni bawk.
Tirzepatide hi kar khatah vawi khat subcutaneous injection hmanga pek thin a ni tlangpui a, nitin insulin emaw zunthlum enkawlna dang emaw nena khaikhin chuan damlote tan awlsamna a pe thin. Side effects-ah chuan natna, luak chhuak, luak chhuak, leh ei duhna tlahniam te a awm thei a, chu chu hun kal zelah a tlahniam fo thin. Mahse, damdawi dang ang bawkin, damlote tan chuan an healthcare provider, a bik takin pancreatitis emaw thyroid emaw nei tawhte nen hlauhawm leh hlawkna awm thei te sawiho a pawimawh hle.
A theihna zau zawk chungchanga zirchianna kalpui mek, cardiovascular health leh non-Alcoholic fatty liver disease-a hman a nih avangin, Tirzepatide hian metabolic disorder enkawlna kawngah hmasawnna nasa tak a entir a ni.